Watch our webinar with Microba Life Sciences, featuring CEO Dr Luke Reid. An interview followed by live Q&A with the audience.

Microba Life Sciences is a commercial-stage diagnostic and clinical-stage drug development company, focused on combating disease through microbiome health. Founded in 2017 from technology developed at The University of Queensland, Microba is dedicated to discovering and developing novel therapeutics for major chronic diseases, and delivering diagnostic microbiome testing on a global scale.
The human gut microbiome represents one of the greatest untapped opportunities to improve human health. Over the past decade, research has increasingly shown that the gut microbiome plays a crucial role in various aspects of health and disease. Microba's founding vision is that microbiome testing and therapeutics will become a routine part of healthcare, a goal made possible by the company’s world-leading technology.
Microba employs a human-first, data-driven approach to identify therapeutic leads that are naturally derived from a healthy human gut. By leveraging a globally unique, proprietary databank, the company has established a robust and repeatable Therapeutic Platform capable of developing multiple candidates to address large unmet clinical needs in chronic diseases.
Microba is a leader in diagnostic microbiome testing, and has forged key partnerships with some of the world's largest medical diagnostic companies, including Sonic Healthcare and SYNLAB.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.